Literature DB >> 24602192

Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma.

Emily S West1, Victoria L Williams, Joseph G Morelli.   

Abstract

Neutrophilic panniculitis is a rare adverse effect of therapy with selective BRAF inhibitors. We report a case of neutrophilic panniculitis in a 15-year-old girl receiving treatment with vemurafenib for a brainstem glioma. Clinicians should be aware of this rare but important side effect of vemurafenib. This is the first report of neutrophilic panniculitis in a child treated with vemurafenib.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24602192     DOI: 10.1111/pde.12316

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  5 in total

1.  Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis.

Authors:  Nina Anika Richarz; Luis Puig; Noelia Pérez; Jose Cuadra-Urteaga; Elena Elez; Maria Teresa Fernández-Figueras
Journal:  Cancer Biol Ther       Date:  2018-11-14       Impact factor: 4.742

Review 2.  Advances in the management of low-grade gliomas.

Authors:  Amulya A Nageswara Rao; Roger J Packer
Journal:  Curr Oncol Rep       Date:  2014       Impact factor: 5.075

3.  MicroRNA-520d-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting PTTG1.

Authors:  Tongle Zhi; Kuan Jiang; Xiupeng Xu; Tianfu Yu; Weining Wu; Er Nie; Xu Zhou; Xin Jin; Junxia Zhang; Yingyi Wang; Ning Liu
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

4.  Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.

Authors:  Francesca del Bufalo; Andrea Carai; Lorenzo Figà-Talamanca; Benedetta Pettorini; Conor Mallucci; Felice Giangaspero; Manila Antonelli; Manuela Badiali; Loredana Moi; Giuseppe Bianco; Antonella Cacchione; Franco Locatelli; Elisabetta Ferretti; Angela Mastronuzzi
Journal:  J Transl Med       Date:  2014-12-19       Impact factor: 5.531

5.  Delayed-onset vemurafenib-induced panniculitis.

Authors:  Stephen L Vance; Hannah M Singer; David Silvers; Sameera Husain; Filamer Kabigting
Journal:  JAAD Case Rep       Date:  2017-08-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.